|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
| |
|
|
|
 |
Debu Tripathy, MD
Professor of Internal Medicine
Director, Komen UT Southwestern
Breast Cancer Research Program
University of Texas Southwestern Medical Center
Dallas, Texas
Click here to download the entire interview |
WMA |
MP3 |
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Continuation of trastuzumab after disease progression |
|
|
| Track 3 |
Mechanisms of action of trastuzumab |
|
|
| Track 4 |
New classification systems for breast cancer |
|
|
| Track 5 |
Outcomes of patients continuing trastuzumab after progression in the pivotal trial |
|
|
| Track 6 |
Clinical use of trastuzumab after disease progression |
|
|
| Track 7 |
Perspectives on the MD Anderson neoadjuvant trastuzumab trial |
|
|
| Track 8 |
Discussing the option of neoadjuvant/adjuvant trastuzumab with patients |
|
|
| Track 9 |
Management of ER-positive, HER2-positive disease |
|
|
| Track 10 |
First-line use of trastuzumab monotherapy for patients with ER-negative, HER2-positive metastatic disease |
|
|
| Track 11 |
Up-front use of adjuvant aromatase inhibitors |
|
|
| Track 12 |
Continuation of an aromatase inhibitor after five years of therapy |
|
|
| Track 13 |
Increased incidence of myocardial infarction observed in the BIG 1-98 trial with letrozole |
|
|
| Track 14 |
Switching from tamoxifen to an aromatase inhibitor |
|
|
| Track 15 |
Selection of adjuvant aromatase inhibitors at various time points in treatment |
|
|
| Track 16 |
Patient preferences for oral endocrine therapy versus intramuscular treatment |
|
|
| Track 17 |
Potential benefits of nanoparticle albumin-bound (nab) paclitaxel |
|
|
| Track 18 |
Selection of chemotherapeutic regimens in the metastatic setting |
|
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Similarities and differences between neoadjuvant chemotherapy and endocrine therapy |
|
|
| Track 3 |
Improved rates of breast-conserving surgery with neoadjuvant endocrine therapy |
|
|
| Track 4 |
Differences in side-effect profiles of aromatase inhibitors |
|
|
| Track 5 |
Indirect comparison of data from ATAC and BIG 1-98 |
|
|
| Track 6 |
Increased number of cardiac deaths observed in BIG 1-98 |
|
|
| Track 7 |
Hypercholesterolemia and cardiac toxicity with endocrine therapies |
|
|
| Track 8 |
Switching from tamoxifen to an aromatase inhibitor after two to three years |
|
|
| Track 9 |
Initiating therapy with an aromatase inhibitor after five years of tamoxifen |
|
|
| Track 10 |
Potential benefit of preoperative therapy with an aromatase inhibitor |
|
|
| Track 11 |
Correlation between number of sentinel lymph nodes and false-negative rate |
|
|
| Track 12 |
Morbidity associated with axillary dissection after sentinel lymph node biopsy |
|
|
| Track 13 |
Genomic changes that predict for response following neoadjuvant aromatase inhibitors |
|
|
| Track 14 |
Differences between intratumoral effects of tamoxifen and aromatase inhibitors |
|
|
| Track 15 |
Aromatase inhibitors in patients with ER-positive, HER2-positive disease |
|
|
| Track 16 |
Optimal dosing of fulvestrant |
|
|
| Track 17 |
Potential role for combining fulvestrant and anastrozole |
|
|
| |
|
|
|
 |
Nancy E Davidson, MD
Professor of Oncology
Breast Cancer Research Chair in Oncology
Director of the Breast Cancer Research Program
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Epigenetic mechanisms to silence estrogen receptor gene expression |
|
|
| Track 3 |
Potential role of histone deacetylase inhibitors in the management of breast cancer |
|
|
| Track 4 |
Pilot study of breast density changes in postmenopausal women receiving anastrozole |
|
|
| Track 5 |
Design and initial results from BIG 1-98 |
|
|
| Track 6 |
Cardiac toxicity observed with aromatase inhibitors |
|
|
| Track 7 |
Pilot study of preoperative dose-dense docetaxel |
|
|
| Track 8 |
Case discussion: A young woman with an acute allergic reaction to docetaxel |
|
|
| Track 9 |
Sequencing capecitabine in the treatment algorithm |
|
|
| Track 10 |
Advantage of avoiding premedication with nab paclitaxel |
|
|
| Track 11 |
Ongoing trials of ovarian suppression plus hormonal therapy in premenopausal patients |
|
|
| Track 12 |
Nonprotocol use of adjuvant ovarian suppression with hormonal therapy for premenopausal patients |
|
|
| Track 13 |
Ovarian suppression with chemotherapy to preserve fertility |
|
|
| Track 14 |
Selection of chemotherapeutic regimen to preserve menstrual function |
|
|
| Track 15 |
Counseling patients about fertility and childbearing after breast cancer |
|
|
| Track 16 |
Hormone replacement therapy following breast cancer |
|
|
| Track 17 |
Impact of hormonal changes on breast cancer occurring during pregnancy |
|
|
| Track 18 |
Management of breast cancer in patients diagnosed during pregnancy |
|
|
|
|
